ClinicalTrials.gg
Sign In
CompletedNCT06545877Updated Sep 3, 2026

REKOVELLE PEN for S.C. Injection General Drug Use Survey (Controlled Ovarian Stimulation in Assisted Reproductive Technologies)

An observational study in Infertility, sponsored by Ferring Pharmaceuticals. Completed at 1 site in Japan. Open to female participants. Per ClinicalTrials.gov, last updated 2026-09-03.

Sponsored by Ferring Pharmaceuticals · Observational

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
571
Sex
Female
01

Study summary

This survey targets controlled ovarian stimulation with this drug for the development of multiple oocytes in women undergoing assisted reproduction (ART) such as in vitro fertilization (IVF) or intracytoplasmic sperm injection (ICSI).

02

Conditions studied

  • Infertility

Browse trials for

03

In context

Infertility

2,085 studies on the registry are indexed under Infertility; 357 are open to participants now.

This study's enrollment of 571 is above the median of 200 across 592 observational studies indexed under Infertility.

Browse Infertility studies →

Lead sponsor

Ferring Pharmaceuticals is the lead sponsor of 249 studies on the registry; 4 are open to participants now.

Of its 15 completed or terminated interventional studies of FDA-regulated products, 14 (93%) have results posted.

Browse Ferring Pharmaceuticals studies →

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
Female
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Women who are undergoing assisted reproduction (ART) such as in vitro fertilization (IVF) or intracytoplasmic sperm injection (ICSI).

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants who received the REKOVELLE in controlled ovarian stimulation in assisted reproductive technologies and have consented to participate in the survey.

Exclusion criteria

Exclusion Criteria:

  • No exclusion criteria because data are collected under conditions of use in daily practice.
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
571 participants (actual)
Patient registry
No
06

What researchers measure

Primary outcomes

  1. Adverse Events

    Frequency of Adverse Events

    Time frame: From initiation of the administration, in case of embryo transfer is not performed, until 1 week after oocyte collection, and in case embryo transfer is performed, 6 weeks after embryo transfer

07

Study locations

1 site
  • Ferring Investigational Site
    Omitama, Ibaraki, Japan
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Sep 2022 to primary completion in Apr 2025, 31 months.

Of 242 observational studies under Infertility, half reached primary completion within 39 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 100. This study's 31 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 6, 2024
First posted
Aug 9, 2024
StartActual
Sep 16, 2022
Primary completionActual
Apr 30, 2025
CompletionActual
Feb 28, 2026
Last update
Sep 3, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 3, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06545877
Lead sponsor
Ferring Pharmaceuticals
Responsible party
Sponsor
First posted
Aug 9, 2024
Start date
Sep 16, 2022
Primary completion
Apr 30, 2025
Completion
Feb 28, 2026
Last update
Sep 3, 2026

Study contacts

Global Clinical Compliance
study director · Ferring Pharmaceuticals

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Other studies in this condition

Infertility →

Other studies from this sponsor

Ferring Pharmaceuticals →

Start the discussion